5x22 › Citations

Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase.

Maffioli SI, Zhang Y, Degen D, Carzaniga T, Del Gatto G, Serina S, Monciardini P, Mazzetti C, Guglierame P, Candiani G, Chiriac AI, Facchetti G, Kaltofen P, Sahl HG, Dehò G, Donadio S, Ebright RH
Cell 169 1240-1248.e23 (2017)
Cited: 56 times
EuropePMC logo PMID: 28622509

Abstract

Drug-resistant bacterial pathogens pose an urgent public-health crisis. Here, we report the discovery, from microbial-extract screening, of a nucleoside-analog inhibitor that inhibits bacterial RNA polymerase (RNAP) and exhibits antibacterial activity against drug-resistant bacterial pathogens: pseudouridimycin (PUM). PUM is a natural product comprising a formamidinylated, N-hydroxylated Gly-Gln dipeptide conjugated to 6'-amino-pseudouridine. PUM potently and selectively inhibits bacterial RNAP in vitro, inhibits bacterial growth in culture, and clears infection in a mouse model of Streptococcus pyogenes peritonitis. PUM inhibits RNAP through a binding site on RNAP (the NTP addition site) and mechanism (competition with UTP for occupancy of the NTP addition site) that differ from those of the RNAP inhibitor and current antibacterial drug rifampin (Rif). PUM exhibits additive antibacterial activity when co-administered with Rif, exhibits no cross-resistance with Rif, and exhibits a spontaneous resistance rate an order-of-magnitude lower than that of Rif. PUM is a highly promising lead for antibacterial therapy.

Reviews - 5x22 mentioned but not cited (1)

  1. The Mechanisms of Substrate Selection, Catalysis, and Translocation by the Elongating RNA Polymerase. Belogurov GA, Artsimovitch I. J Mol Biol 431 3975-4006 (2019)


Reviews citing this publication (18)

  1. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Seley-Radtke KL, Yates MK. Antiviral Res 154 66-86 (2018)
  2. Biology of antimicrobial resistance and approaches to combat it. Schrader SM, Vaubourgeix J, Nathan C. Sci Transl Med 12 eaaz6992 (2020)
  3. Diverse and unified mechanisms of transcription initiation in bacteria. Chen J, Boyaci H, Campbell EA. Nat Rev Microbiol 19 95-109 (2021)
  4. Combined Antimicrobial Activity of Photodynamic Inactivation and Antimicrobials-State of the Art. Wozniak A, Grinholc M. Front Microbiol 9 930 (2018)
  5. Learning from bacterial competition in the host to develop antimicrobials. Raffatellu M. Nat Med 24 1097-1103 (2018)
  6. The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies. Mantravadi PK, Kalesh KA, Dobson RCJ, Hudson AO, Parthasarathy A. Antibiotics (Basel) 8 E8 (2019)
  7. A Structural View on Medicinal Chemistry Strategies against Drug Resistance. Agnello S, Brand M, Chellat MF, Gazzola S, Riedl R. Angew Chem Int Ed Engl 58 3300-3345 (2019)
  8. Recent advances in synthetic approaches for medicinal chemistry of C-nucleosides. Temburnikar K, Seley-Radtke KL. Beilstein J Org Chem 14 772-785 (2018)
  9. Recent advances in the biosynthesis of nucleoside antibiotics. Shiraishi T, Kuzuyama T. J Antibiot (Tokyo) 72 913-923 (2019)
  10. Identification and characterization of enzymes involved in the biosynthesis of pyrimidine nucleoside antibiotics. McErlean M, Liu X, Cui Z, Gust B, Van Lanen SG. Nat Prod Rep 38 1362-1407 (2021)
  11. Biosynthesis of C-nucleoside antibiotics in actinobacteria: recent advances and future developments. Zhang M, Kong L, Gong R, Iorio M, Donadio S, Deng Z, Sosio M, Chen W. Microb Cell Fact 21 2 (2022)
  12. Development and Research Progress of Anti-Drug Resistant Bacteria Drugs. Cui X, Lü Y, Yue C. Infect Drug Resist 14 5575-5593 (2021)
  13. Discovery, properties, and biosynthesis of pseudouridimycin, an antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase. Maffioli SI, Sosio M, Ebright RH, Donadio S. J Ind Microbiol Biotechnol 46 335-343 (2019)
  14. Effective approaches to discover new microbial metabolites in a large strain library. Zdouc MM, Iorio M, Vind K, Simone M, Serina S, Brunati C, Monciardini P, Tocchetti A, Zarazúa GS, Crüsemann M, Maffioli SI, Sosio M, Donadio S. J Ind Microbiol Biotechnol 48 kuab017 (2021)
  15. RNA polymerases from low G+C gram-positive bacteria. Miller M, Oakley AJ, Lewis PJ. Transcription 12 92-102 (2021)
  16. Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19. Das R, Kotra K, Singh P, Loh B, Leptihn S, Bajpai U. Infect Dis Ther 11 53-78 (2022)
  17. Engineering nucleoside antibiotics toward the development of novel antimicrobial agents. Niu G, Li Z, Huang P, Tan H. J Antibiot (Tokyo) 72 906-912 (2019)
  18. [New inhibitors targeting bacterial RNA polymerase]. Shi J, Feng Y. Zhejiang Da Xue Xue Bao Yi Xue Ban 48 44-49 (2019)

Articles citing this publication (37)

  1. In-cell architecture of an actively transcribing-translating expressome. O'Reilly FJ, Xue L, Graziadei A, Sinn L, Lenz S, Tegunov D, Blötz C, Singh N, Hagen WJH, Cramer P, Stülke J, Mahamid J, Rappsilber J. Science 369 554-557 (2020)
  2. Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3). Lin W, Das K, Degen D, Mazumder A, Duchi D, Wang D, Ebright YW, Ebright RY, Sineva E, Gigliotti M, Srivastava A, Mandal S, Jiang Y, Liu Y, Yin R, Zhang Z, Eng ET, Thomas D, Donadio S, Zhang H, Zhang C, Kapanidis AN, Ebright RH. Mol Cell 70 60-71.e15 (2018)
  3. Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis. Mosaei H, Molodtsov V, Kepplinger B, Harbottle J, Moon CW, Jeeves RE, Ceccaroni L, Shin Y, Morton-Laing S, Marrs ECL, Wills C, Clegg W, Yuzenkova Y, Perry JD, Bacon J, Errington J, Allenby NEE, Hall MJ, Murakami KS, Zenkin N. Mol Cell 72 263-274.e5 (2018)
  4. Analysis of the Pseudouridimycin Biosynthetic Pathway Provides Insights into the Formation of C-nucleoside Antibiotics. Sosio M, Gaspari E, Iorio M, Pessina S, Medema MH, Bernasconi A, Simone M, Maffioli SI, Ebright RH, Donadio S. Cell Chem Biol 25 540-549.e4 (2018)
  5. Molecular modeling studies of pseudouridine isoxazolidinyl nucleoside analogues as potential inhibitors of the pseudouridine 5'-monophosphate glycosidase. Floresta G, Pistarà V, Amata E, Dichiara M, Damigella A, Marrazzo A, Prezzavento O, Punzo F, Rescifina A. Chem Biol Drug Des 91 519-525 (2018)
  6. Identification of the C-Glycoside Synthases during Biosynthesis of the Pyrazole-C-Nucleosides Formycin and Pyrazofurin. Ren D, Wang SA, Ko Y, Geng Y, Ogasawara Y, Liu HW. Angew Chem Int Ed Engl 58 16512-16516 (2019)
  7. Pseudouridimycin: The First Nucleoside Analogue That Selectively Inhibits Bacterial RNA Polymerase. Chellat MF, Riedl R. Angew Chem Int Ed Engl 56 13184-13186 (2017)
  8. Divergent Biosynthesis of C-Nucleoside Minimycin and Indigoidine in Bacteria. Kong L, Xu G, Liu X, Wang J, Tang Z, Cai YS, Shen K, Tao W, Zheng Y, Deng Z, Price NPJ, Chen W. iScience 22 430-440 (2019)
  9. Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3. Sherstyuk YV, Ivanisenko NV, Zakharenko AL, Sukhanova MV, Peshkov RY, Eltsov IV, Kutuzov MM, Kurgina TA, Belousova EA, Ivanisenko VA, Lavrik OI, Silnikov VN, Abramova TV. Int J Mol Sci 21 E214 (2019)
  10. Identifying the role of PrimPol in TDF-induced toxicity and implications of its loss of function mutation in an HIV+ patient. Duong VN, Zhou L, Martínez-Jiménez MI, He L, Cosme M, Blanco L, Paintsil E, Anderson KS. Sci Rep 10 9343 (2020)
  11. Reverse C-glycosidase reaction provides C-nucleotide building blocks of xenobiotic nucleic acids. Pfeiffer M, Nidetzky B. Nat Commun 11 6270 (2020)
  12. Active site closure stabilizes the backtracked state of RNA polymerase. Turtola M, Mäkinen JJ, Belogurov GA. Nucleic Acids Res 46 10870-10887 (2018)
  13. Anticancer efficiency of cycloartane triterpenoid derivatives isolated from Cimicifuga yunnanensis Hsiao on triple-negative breast cancer cells. Li X, Wang W, Fan Y, Wei Y, Yu LQ, Wei JF, Wang YF. Cancer Manag Res 10 6715-6729 (2018)
  14. Blocks in the pseudouridimycin pathway unlock hidden metabolites in the Streptomyces producer strain. Iorio M, Davatgarbenam S, Serina S, Criscenzo P, Zdouc MM, Simone M, Maffioli SI, Ebright RH, Donadio S, Sosio M. Sci Rep 11 5827 (2021)
  15. Characterization of C-nucleoside Antimicrobials from Streptomyces albus DSM 40763: Strepturidin is Pseudouridimycin. Rosenqvist P, Palmu K, Prajapati RK, Yamada K, Niemi J, Belogurov GA, Metsä-Ketelä M, Virta P. Sci Rep 9 8935 (2019)
  16. Facile Solid-Phase Synthesis and Assessment of Nucleoside Analogs as Inhibitors of Bacterial UDP-Sugar Processing Enzymes. Madec AGE, Schocker NS, Sanchini S, Myratgeldiyev G, Das D, Imperiali B. ACS Chem Biol 13 2542-2550 (2018)
  17. Functionalised bicyclic tetramates derived from cysteine as antibacterial agents. Panduwawala TD, Iqbal S, Thompson AL, Genov M, Pretsch A, Pretsch D, Liu S, Ebright RH, Howells A, Maxwell A, Moloney MG. Org Biomol Chem 17 5615-5632 (2019)
  18. Oxazinomycin arrests RNA polymerase at the polythymidine sequences. Prajapati RK, Rosenqvist P, Palmu K, Mäkinen JJ, Malinen AM, Virta P, Metsä-Ketelä M, Belogurov GA. Nucleic Acids Res 47 10296-10312 (2019)
  19. Evaluation of Bacterial RNA Polymerase Inhibitors in a Staphylococcus aureus-Based Wound Infection Model in SKH1 Mice. Haupenthal J, Kautz Y, Elgaher WAM, Pätzold L, Röhrig T, Laschke MW, Tschernig T, Hirsch AKH, Molodtsov V, Murakami KS, Hartmann RW, Bischoff M. ACS Infect Dis 6 2573-2581 (2020)
  20. Heterologous Expression of Pseudouridimycin and Description of the Corresponding Minimal Biosynthetic Gene Cluster. Böhringer N, Patras MA, Schäberle TF. Molecules 26 510 (2021)
  21. The mechanism of the nucleo-sugar selection by multi-subunit RNA polymerases. Mäkinen JJ, Shin Y, Vieras E, Virta P, Metsä-Ketelä M, Murakami KS, Belogurov GA. Nat Commun 12 796 (2021)
  22. Tocopherol polyethylene glycol succinate-modified hollow silver nanoparticles for combating bacteria-resistance. Kang XQ, Qiao Y, Lu XY, Jiang SP, Li WS, Wang XJ, Xu XL, Qi J, Xiao YH, Du YZ. Biomater Sci 7 2520-2532 (2019)
  23. Pseudouridimycin: Light in the Darkness of Antimicrobial Resistance. O'Malley PA. Clin Nurse Spec 32 114-115 (2018)
  24. An Optimized Workflow for the Discovery of New Antimicrobial Compounds Targeting Bacterial RNA Polymerase Complex Formation. Caputo A, Sartini S, Levati E, Minato I, Elisi GM, Di Stasi A, Guillou C, Goekjian PG, Garcia P, Gueyrard D, Bach S, Comte A, Ottonello S, Rivara S, Montanini B. Antibiotics (Basel) 11 1449 (2022)
  25. Coagulation factors: a novel class of endogenous host antimicrobial proteins against drug-resistant gram-negative bacteria. Li C, You X. Signal Transduct Target Ther 4 46 (2019)
  26. GPI0363 inhibits the interaction of RNA polymerase with DNA in Staphylococcus aureus. Paudel A, Panthee S, Hamamoto H, Sekimizu K. RSC Adv 9 37889-37894 (2019)
  27. The race for antimicrobials in the multidrug resistance era. Molina-Santiago C, de Vicente A, Romero D. Microb Biotechnol 11 976-978 (2018)
  28. A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Wee LM, Tong AB, Florez Ariza AJ, Cañari-Chumpitaz C, Grob P, Nogales E, Bustamante CJ. Cell 186 1244-1262.e34 (2023)
  29. Interview Novel RNA polymerase inhibitor found in soil extracts provides hope for future antibacterial drugs. Ebright RH. Future Med Chem 9 1857-1861 (2017)
  30. Pseudouridine-Modifying Enzymes SapB and SapH Control Entry into the Pseudouridimycin Biosynthetic Pathway. Artukka E, Schnell R, Palmu K, Rosenqvist P, Szodorai E, Niemi J, Virta P, Schneider G, Metsä-Ketelä M. ACS Chem Biol 18 794-802 (2023)
  31. "Upcycling" known molecules and targets for drug-resistant TB. Roubert C, Fontaine E, Upton AM. Front Cell Infect Microbiol 12 1029044 (2022)
  32. Antibacterials: PUMmeling RNAP. Sheppard TL. Nat Chem Biol 13 817 (2017)
  33. Biosynthesis and Genome Mining Potentials of Nucleoside Natural Products. Du Y, Thanapipatsiri A, Yokoyama K. Chembiochem 24 e202300342 (2023)
  34. Genomic New Insights Into Emergence and Clinical Therapy of Multidrug-Resistant Klebsiella pneumoniae in Infected Pancreatic Necrosis. Hao H, Liu Y, Cao J, Gao K, Lu Y, Wang W, Wang P, Lu S, Hu L, Tong Z, Li W. Front Microbiol 12 669230 (2021)
  35. Infectious diseases: Soil-sifting snags new antibiotic. Kingwell K. Nat Rev Drug Discov 16 530 (2017)
  36. Isolation, Characterization, and Antimicrobial Activity of Bacterial and Fungal Representatives Associated With Particulate Matter During Haze and Non-haze Days. Yan D, Zhang T, Bai JL, Su J, Zhao LL, Wang H, Fang XM, Zhang YQ, Liu HY, Yu LY. Front Microbiol 12 793037 (2021)
  37. Pseudouridimycin-A Potent Nucleoside Inhibitor of the RNA Polymerase Beta Prime Subunit of Streptococcus pyogenes. Pavundurai Chandra K, Perumal D, Ragunathan P. ACS Omega 8 7989-8000 (2023)


Quick links